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Abstract
CD137 (4-1BB, TNFRSF9), a member of the tumor necrosis factor (TNF) receptor family, is a potent T cell
co-stimulatory molecule. CD137 ligand (CD137L) is expressed by antigen presenting cells (APC) as a transmembrane
protein and transmits activating signals into APC. In this study we investigated the effects of CD137L signaling in
microglia, the resident APC in the central nervous system. In vitro, the murine microglia cell lines BV-2 and N9, as
well as primary murine microglia responded with activation as evidenced by adherence and secretion of
proinflammatory cytokines, MMP-9, and soluble intercellular adhesion molecule (ICAM). CD137L signaling is also
important for microglia activation in vivo, since CD137L-deficient mice exhibited profoundly less microglia activation
during experimental autoimmune encephalomyelitis (EAE) which is a well-established murine model for
neuroinflammation and human multiple sclerosis (MS). Also CD137 is expressed in the CNS of mice during EAE.
Activated microglia has been reported to mediate the destruction of axonal myelin sheaths and cause the death of
oligodendrocytes, the main pathogenic mechanisms in EAE and MS. Corresponding to the lower microglia
activation there were also fewer apoptotic oligodendrocytes in the CNS of CD137L-deficient mice. In vitro
co-culture confirmed that CD137L-activated microglia induces apoptosis in oligodendrocytes, and identified reactive
oxygen species as the mechanism of apoptosis induction. These data demonstrate activating effects of CD137L
signaling to microglia, and show for the first time that the CD137 receptor/ligand system may be a mediator of
neuroinflammatory and neurodegenerative disease, by activating microglia which in turn kill oligodendrocytes.
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Background
Multiple sclerosis (MS) is a severe autoimmune disease
of the central nervous system (CNS), characterized by
the loss of axonal myelin sheaths that leads to neuronal
degeneration and subsequently to neurological and be-
havioral abnormalities. A major problem with MS is that
we do not know its cause and that we only poorly
understand its pathogenesis. A considerable amount of
MS research is being carried out using experimental
autoimmune encephalomyelitis (EAE), a murine model
of neuroinflammation that mimics some aspects of MS
[1,2].
CD137 (TNFRSF9, 4-1BB, induced by lymphocyte acti-
vation, ILA) is a member of the tumor necrosis factor
(TNF) receptor family which is expressed on activated T
cells, NK cells, and vascular endothelial cells and deli-
vers potent co-stimulatory signals upon activation [3-6].
CD137L is expressed by APC, and APC use CD137L
to co-stimulate CD137-expressing, activated T cells. The
CD137 receptor/ligand system is capable of bidirectional
signaling, a property it shares with several other mem-
bers of the TNF receptor/ligand families [7]. The mo-
lecular basis of bidirectional signaling is that CD137L,
just as CD137, is expressed as a transmembrane protein
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on the cell surface and that it can transmit a signal into
the cell it is expressed on, a process referred to as re-
verse signaling [8].
Reverse signaling by CD137L activates peripheral
monocytes evidenced by stronger adhesion, secretion of
proinflammatory cytokines [9,10], increased survival
[11], proliferation [12], and enhanced migration [13].
Further, CD137L signaling induces differentiation of
monocytes to dendritic cells (DC) and DC maturation
[14-16]. Even hematopoietic progenitor cells are stimu-
lated by CD137L signaling which respond with prolifera-
tion and myeloid differentiation [17,18]. These data
identify CD137L as potent growth factor for myeloid
cells. Therefore, we hypothesized that CD137L signaling
may also activate microglia which are the resident APC
of myeloid origin in the CNS [19,20].
Our study confirms this hypothesis. CD137L signaling
activates microglia cell lines and primary microglia cells
in vitro leading to enhanced adhesion and secretion of
proinflammatory cytokines. CD137L is also important
for microglia activation in vivo, as its absence in genetic-
ally modified mice results in lower microglia activation
during EAE. A key event in the pathogenesis of EAE and
MS is the destruction of oligodendrocytes and their
axonal myelin sheaths by activated immune cells.
CD137L-activated microglia indeed induces apoptosis in
oligodendrocytes and this cell death is mediated by re-
active oxygen species (ROS).
Methods
Culture of murine microglia cell lines
The murine microglia cell line BV-2 was purchased from
Banca Biologica e Cell Factory (IST Genova, Italy). BV-2
cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) high glucose medium (Sigma) con-
taining 10% fetal bovine serum (Biowest) at 37°C in 5%
CO2. Growth medium was changed every 3 to 4 days be-
fore cells reached confluence. The N9 cell line was a gift
from Dr Wong Siew Heng from the Department of
Microbiology, NUS. DMEM high glucose medium
(Sigma) containing 10% fetal bovine serum (Biowest)
culture medium was also employed for the culture of
the murine N9 cell line. Growth medium was changed
every 2 to 3 days until confluence was reached.
Primary microglia culture
Six-to-eight-week-old female C57BL/6 mice were deeply
anaesthetized with pentobarbitone (90 mg/kg). Transcardial
perfusion was performed using 0.9% NaCl with ice cold
heparin. Brain and spinal cord tissues were extracted and
processed using the MACS Neural Tissue Dissociation kit
and the GentleMACS Tissue Dissociator (Miltenyi).
Manual cell count was performed using trypan blue stain-
ing, and the cells were resuspended in DMEM high glucose
containing 10% fetal bovine serum (FBS), 1 x penicillin
streptomycin (Life Technologies) and 10 ng/mL M-CSF
(Peprotech). A seeding density of 1.5 x 106 cells per mL was
employed and cells were incubated for up to 4 days at 37°C
in 5% CO2. Growth medium with 10 ng/mL M-CSF was
supplied every 3 to 4 days for up to 4 weeks.
Induction of CD137L signaling
Tissue culture plates were coated with PBS, 10 μg/mL of
human Fc fragment (Millipore, Temecula, CA, USA) or
10 μg/mL human CD137-Fc (R&D Systems) overnight at
4°C. Then the wells were rinsed and cells were plated.
For microglia and OLN93 co-cultures, either primary
microglia or BV-2 or N9 cells were co-cultured with
OLN93 cells on PBS-, Fc-, and CD137-Fc-coated plates
overnight. Murine microglia cells were labeled with 2
μM carboxyfluorescein succinimidyl ester (CFSE), (Invi-
trogen) prior to co-culture. A total of 10,000 U/mL of
catalase were added to designated wells.
Antibodies and flow cytometry
Phycoerythrin (PE)-conjugated and unconjugated anti-
mouse CD137 antibody (clone 17B5) and anti-mouse
CD137 ligand antibody (clone TKS-1) were obtained
from eBioscience (San Diego, CA, USA). PE or fluores-
cein isothiocyanate (FITC) labeled rat anti-mouse
CD11b, CD45, and respective isotype controls (rat
IgG2a, rat IgG2b, Armenian Hamster IgG) were pur-
chased from eBioscience. Non-specific staining was con-
trolled by isotype-matched antibodies. For assessment of
apoptosis, cells were stained with 7-AAD (BD Pharmin-
gen) and Annexin V Alexa Fluor 647 (BioLegend). Flow
cytometry was performed either on a FACSCalibur (BD
Biosciences, San Jose, CA) with CellQuest data acquisi-
tion and analysis software, or on a Cyan flow cytometer
(Dako, Denmark) with Summit software.
Photographs
Morphological changes of cells were documented using
a Zeiss Axiovert 40 inverted microscope (Zeiss, Göttin-
gen, Germany) and Canon PowerShot G6 digital camera.
Phagocytosis assay
Fifty yellow-green fluorescent latex beads of 1 μm diam-
eter (FluoSpheresW, Molecular Probes) per cell were
added to samples and incubated for 1 h at 37°C. Subse-
quently, phagocytosis was stopped by the addition of
ice-cold PBS and cells were washed and treated with
trypsin to dislodge any surface adherent latex beads.
Cells were then resuspended in 400 μL PBS and flow
cytometry was performed to quantify phagocytosis.
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ROS measurements
After 24 h of culture in wells coated with PBS, Fc, or
CD137-Fc the cells were stimulated with 0.4 μg/mL
PMA treatment for 1.5 h, and then stained with 100 ng/mL
of dihydrorhodamine (DHR123, Invitrogen) for 25 min at
37°C. Then cells were washed to remove excess DHR123.
ROS production was quantified using the FITC channel
on a Cyan flow cytometer.
ELISA
ELISA assays for TNF, sICAM-1, and Total MMP-9
(R&D Systems), and MCP-1, IL-1β, IL-6, and IL-12 p40
(Peprotech) were performed according to the manufac-
turers’ protocols. All measurements were performed in
triplicates.
EAE induction
All institutional guidelines for animal care and use were
strictly adhered throughout the experiments. C57BL/6
mice were obtained from the Centre for Animal Resources
(CARE) of the National University of Singapore, and
CD137L-/- mice were a gift from Amgen and bred in-
house under pathogen-free conditions. Mice were injected
subcutaneously with 100 μg of myelin oligodendrocyte
glycoprotein peptide fragment 35-55 (MOG35-55) (Sigma-
Aldrich) and 1 mg heat-killed Mycobacterium tuberculosis
H37RA (Difco) emulsified in complete Freund’s adjuvant.
Pertussis toxin (200 ng in PBS; List Biological Laborator-
ies) was injected intraperitoneally on days 0 and 2 after
immunization. EAE clinical symptoms were scored daily
as follows: 0, no clinical signs; 1, loss of tail tonicity; 2,
impaired righting reflex; 3, partial hind limb paralysis; and
4, total hind limb paralysis.
Immunohistochemistry (IHC)
Transcardial perfusion was performed prior to sacrificing
the mice. CNS tissues from naive and EAE mice were
extracted and fixed with 10% neutral buffered formalin for
3 days. The tissues were paraffin-embedded and serially
sectioned at 5 μM thickness (Leica Microsystems). After
deparaffinization in Histo-Clear, and hydration in a graded
series of alcohol, the slides were pretreated with citrate
buffer (Dako) in a pressure cooker at 109°C for 20 min for
antigen retrieval. Unspecific staining was blocked by 2%
serum for 30 min. Endogenous peroxidases were inacti-
vated by 3% hydrogen peroxide for 15 min. Anti-CD137
(goat polyclonal, R&D Systems) and anti-Iba-1 (rabbit
polyclonal, Wako Chemicals) in PBS were used as primary
antibodies and hybridized overnight. The secondary
Strepavidin-HRP (Sigma) was added for 1 h, followed by
DAB+ substrate (Dako). The entire procedure was carried
out at room temperature, and after each step the samples
were washed three times using PBS with 0.05% Tween 20.
The tissue sections were counterstained with hematoxylin
and excess counterstain was washed off with distilled
water. Finally, the stained slides were dehydrated in a
graded series of alcohol followed by Histo-Clear and
mounted.
TUNEL and immunofluorescence stainings
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay (Genscript) was performed on
murine WT and CD137L-/- CNS tissues according to
manufacturer’s instructions. Oligodendrocytes, activated
microglia, and nuclei were visualized with cyanine (Cy)
3-conjugated anti-Nogo-A (sheep polyclonal, R&D Sys-
tems), Cy5-conjugated anti-Iba1 (rabbit polyclonal,
Wako Chemicals), and DAPI, respectively.
Immunofluorescence quantification
The Metamorph NX software (Molecular Devices, Sun-
nyvale, CA, USA) was employed for the quantification of
Cy5-positive activated microglia as well as TUNEL FITC
and Cy3 double-positive dead oligodendrocytes in WT
and CD137L-/- CNS. Cells between 8 and 30 μm in
width with intensity of more than 10 units above back-
ground were gated. The data are presented as means ±
standard deviations of measurements recorded from
three to four separate fields across serial tissue sections,
representing three independent experiments.
Statistical analysis
Data are presented as means ± standard deviations. Stu-
dent’s t-test was used to determine significant differences
between control and treated groups. P<0.05 was regarded
as statistically significant.
Results
Microglia express CD137L and become activated by
CD137L signaling
Our preliminary data lend support to this hypothesis.
CD137L is expressed on primary microglia and on the
microglia cell lines BV-2 and N9. The myeloid nature of
primary microglia was confirmed by staining for CD11b
and CD45 (Figure 1).
Further, CD137L signaling activates microglia.
CD137L signaling in microglia cells was induced with a
recombinant CD137 protein that consists of the extra-
cellular domain of CD137, fused to the constant domain
of human IgG1 (Fc). This CD137-Fc fusion protein was
immobilized on tissue culture plates to allow it to cross-
link CD137L and thereby induce CD137L signaling in
the microglia cells. Uncoated plates (PBS) or plates
coated with Fc protein were used as negative controls.
The activation of microglia by CD137L signaling was
reflected by morphological changes such as increased
adherence and cell spreading. The attachment of pri-
mary microglia on tissue culture plates was already
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visible after 1 h of seeding in the presence of CD137-Fc
but not under the PBS and Fc control conditions
(Figure 2A). Morphological changes of BV-2, N9, and
primary microglia were evident a day after CD137L sig-
naling (Figure 2B).
Further, CD137L engagement induced the secretion of
proinflammatory cytokines (TNF, IL-1, IL-6, IL-12,
MCP-1) in the two microglia cell lines BV-2 and N9
(not shown), and in primary microglia (Figure 2C). Also,
matrix metalloproteinase (MMP)-9 and soluble ICAM
were released by primary microglia in response to
CD137L signaling (Figure 2C) and the phagocytic cap-
acity was increased (Figure 2D).
CD137L is required for microglia activation during
neuroinflammation
After having demonstrated in vitro that CD137L signal-
ing activates microglia we aimed to confirm these data
in vivo. For that we employed EAE, a murine model of
neuroinflammation and human MS. These studies indi-
cate that CD137L is not only able to activate microglia
but seems to be essential. The brain cortices and dorsal
columns of the spinal cords of WT mice with EAE
exhibited strong Iba-1 expression whereas little or no
Iba-1 expression could be detected in corresponding tis-
sues of CD137L-/- mice with EAE (Figure 3A). In the
CD137L-/- mice number of Iba-1+ cells as well as the
staining intensity were significantly reduced (Figure 3B)
indicating that limited redundancy exists to replace the
CD137L signal.
But the absence of CD137L in the CNS of CD137L-/-
mice could only influence the development of EAE
if also CD137 would be present. Indeed, immunohisto-
chemical staining for CD137 confirmed its expression
in the CNS, and expression increased during EAE
(Figure 3C).
CD137L-activated microglia induces apoptosis in
oligodendrocytes
Microglia has been shown to play a pivotal role in EAE
and MS [21,22]. The major pathogenic event in MS is the
killing of oligodendrocytes by activated immune cells, in-
cluding microglia, leading to the loss of axonal myelin
sheaths and the subsequent death of the affected neurons
[23]. Therefore, we investigated the frequency of apoptotic
oligodendrocytes in the CNS of WT and CD137L-/- mice
with EAE by staining for apoptosis-specific DNA frag-
mentation and Nogo-A, an oligodendrocyte marker. The
absence of CD137L, which was associated with much
lower microglia activation also resulted in a lower number
of oligodendrocytes undergoing apoptosis in the dorsal
column of the spinal cord as well as the white matter of
the cerebellum (Figure 3D). For example, nine times more
apoptotic oligodendrocytes could be detected in the cere-
bella of WT mice compared to CD137L-/- mice during
EAE (Figure 3E).
The pathogenesis of EAE in the CD137L-/- mice shows
that reduced microglia activation is associated with a
reduced oligodendrocyte death. In order to provide evi-
dence that the reduced microglia activation is respon-
sible for the reduced oligodendrocyte death we tested
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Figure 1 Expression of CD137L on microglia. Expression of CD137L on the murine microglia cell lines N9 and BV-2 and on C57BL/6 primary
murine microglia was determined by flow cytometry. Open histogram: Isotype control. Grey histogram: Anti-CD137L monoclonal antibody (clone
TKS-1). Primary microglia was also stained for CD11b and CD45. Numbers in panels indicate the percentages of CD137L+ cells.
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In contrast to microglia, CD137L is not expressed by
the oligodendrocyte cell line OLN93 (Figure 4A) and
could also not be detected on primary oligodendrocytes
(not shown). Accordingly, treatment of OLN93 cells
with recombinant CD137-Fc protein had no effect on
cell numbers and the rate of apoptosis (not shown).
When CD137L-activated N9 microglia cells were co-
cultured with OLN93 oligodendrocytes the number of
viable OLN93 cells was significantly reduced compared
to OLN93 cells that had been co-cultured with unacti-
vated microglia or microglia that had been treated with
the Fc control protein (Figure 4B). This decrease in the
live OLN93 cells was also demonstrated with CD137L-
activated primary microglia, and was accompanied by an
induction of apoptotic cell death of the oligodendrocytes
(Figure 4C). Expression of CD137L on microglia was
essential for activation by CD137-Fc protein and its subse-
quent ability to induce oligodendrocyte apoptosis as pri-
mary CD137L-/- microglia had no effect on oligodendrocyte
viability (Figure 4C). Induction of oligodendrocyte apoptosis
could also be shown for microglia cell lines N9 and BV-2
upon activation by CD137L engagement (not shown) con-
firming our hypothesis that CD137L-activated microglia
cause oligodendrocyte apoptosis.
CD137L-activated microglia kills oligodendrocytes via
ROS
CD137L-activated monocytes have been shown to in-
duce apoptosis in of T cells when they are in co-culture,
and this cell death was mediated by ROS [24]. Therefore,
we hypothesized that a similar mechanism may be re-




Figure 2 CD137L signaling activates microglia in vitro. Microglia cells were grown on plates that had been coated with PBS (grey bars) or 10
μg/mL of Fc control protein (white bars) or 10 μg/mL of CD137-Fc protein (black bars). (A) Attachment and morphological changes of primary
microglia were documented by photography (40× magnification) 1 h after plating. Scale bar: 20 μm. (B) Attachment and morphological changes
of BV-2 and N9 cells and primary microglia were documented by photography (63×) 24 h after plating. Cells exposed to immobilized CD137-Fc
protein developed long spiky projections* and became amoeboid cells^ with shortened protrusions#. Scale bar: 20 μm. (C) The concentrations of
cytokines in supernatants of primary microglia were determined by ELISA at indicated time points. Depicted are means ± standard deviations of
triplicate measurements. (D) The phagocytic capacity of the cells was determined by adding FITC-labeled latex beads for 1 h before analysis by
flow cytometry. Control: Autofluorescence of the cells. Numbers above the histograms state the percentages of positive cells and mean
fluorescence intensities (MFI). These experiments were repeated three times with similar results. * P<0.05; ** P<0.01.
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CD137L-activated microglia. Indeed, CD137L engage-
ment on BV-2 cells induced ROS production
(Figure 5A), and when catalase, a hydrogen peroxide
scavenger, was added to the co-culture the killing of oli-
godendrocytes by activated microglia was prevented
(Figure 5B). The percentages of late apoptotic and/or
dead OLN93 cells for the different conditions are quan-
titatively depicted in Figure 5C.
Discussion
The activating effects of CD137L signals on myeloid
cells are well documented [8]. For example, CD137L sig-
naling induces attachment, activation, migration, sur-
vival, proliferation, and differentiation in human
monocytes [9-13,16]. Since microglia, the main resident
myeloid cells in the CNS are similar or identical to tissue
macrophages [19,20] it was surmised that the CD137L
signal activates microglia, and indeed our results con-
firm this notion.
More surprising was the fact that the CD137L signal
seems to be pivotal for microglia activation since consider-
ably fewer activated microglia were found in the CNS of
CD137L-/- mice compared to WT mice during EAE, a
neuroinflammatory disease. This result was unexpected
since activation of macrophages, and microglia, can be
mediated by numerous pathways and is highly redundant.
Microglia has been shown to play a pivotal role in
EAE and MS [21,22]. The major pathogenic event in MS
is the killing of oligodendrocytes by activated immune


































Figure 3 CD137L signaling activates microglia in vivo. (A) CD137L is required for activation of microglia in vivo. Cortex and spinal cord tissue
sections of WT and CD137L-/- mice with EAE were immunohistochemically stained with an isotype control antibody or for Iba-1 (brown). Shown
in the inset is a close-up of a single Iba-1-positive microglia cell in the cortex of a WT mouse with EAE. (B) Quantification of Iba-1+ microglia in
the spinal cords and cortices of WT and CD137L-/- mice with EAE. Evaluated were three fields from two sections each using the Metamorph NX
Software. Depicted are means ± standard deviations. (C) CD137 is expressed in the CNS during EAE. Spinal cord of naïve WT mice and WT mice
with EAE was sectioned and stained with an isotype control antibody or for CD137 (brown). (D) The presence of CD137L is required for
oligodendrocyte apoptosis in EAE. Tissue sections from the dorsal column of the spinal cord and the white matter of the cerebellum of WT and
CD137L-/- mice with EAE were stained for oligodendrocytes using a Cy3-labeled anti-Nogo-A antibody (red). Apoptosis was detected by TUNEL
staining (green). Nuclei were visualized by DAPI (blue). The yellow staining results from an overlay of red and green and indicates apoptotic
oligodendrocytes. Magnification: 40×. (E) Quantification of apoptotic oligodendrocytes in the cerebellum of WT and CD137L-/- mice with EAE.
Evaluated were three fields from two sections each using the Metamorph NX Software. Depicted are means ± standard deviations.
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subsequent death of the demyelinated neurons. Acti-
vated microglia has been demonstrated to induce pro-
grammed cell death in oligodendrocytes [23].
The lower microglia activation in the CNS of
CD137L-/- mice correlated with a lower number of dying
oligodendrocytes during EAE, implying that the micro-
glia caused the oligodendrocyte death. This assumption
could indeed be confirmed by demonstrating in vitro
that CD137L-activated microglia induces oligodendro-
cyte apoptosis. The pathological relevance of this finding
is supported by the fact that both microglia cell lines as
well as primary microglia induced the death of oligoden-
drocytes in response to CD137L signaling. The specifi-
city and essential requirement of CD137L signaling in
this process was demonstrated by the inability of
CD137L-deficient microglia to induce oligodendrocyte
apoptosis.
The induction of oligodendrocyte apoptosis by CD137L-
activated microglia occurs via production of ROS. This par-
allels induction of T cell apoptosis by CD137L-activated
monocytes which occurs during the first 24 h of CD137L
engagement, and which is thought be a mechanism of
infection-induced T cell attrition [24]. Only longer-term
CD137L-signaling induces differentiation of monocytes to
proinflammatory CD137L-DC [15,16].
In general, the CD137L signal seems to induce a
proinflammatory state in myeloid cells as evidenced by
proinflammatory cytokine secretion and ROS production
in microglia and monocytes. Also, CD137L-DC induce T
cells to secrete IFN-γ, IL-13, and IL-17 but to reduce IL-
10 [16].
There is a species difference since murine monocytes
do not differentiate to DC as do human monocytes in
response to CD137L signaling in vitro [25]. However,
in vivo activation of microglia does produce a proinflam-
matory state. Also, in the murine microglia cell lines
BV-2 and N9 a proinflammatory state was induced by
CD137L signaling.
CD137 and its ligand have been shown to influence
the development of EAE. Agonistic anti-CD137 anti-
bodies administered during the induction phase reduced
the incidence and severity of the disease. Potential
mechanisms are an increased activation of T cells and a
subsequent higher rate of activation induced cell death,
as well as a skewing of the T cell response towards regu-
latory T cells [26,27].
Given these data and our findings that in the absence of
CD137L there is less microglia activation and less oligo-
dendrocyte apoptosis one could speculate that EAE induc-
tion in CD137L-/- mice may result in a reduced severity.
However, the effects of CD137 or CD137L manipulations
are very difficult to predict. For example, treatment of
tumor-bearing mice with agonistic anti-CD137 mAb





Figure 4 Induction of oligodendrocyte death by CD137L-activated microglia. (A) Expression of CD137L on the oligodendrocyte cell line
OLN93 was determined by flow cytometry. Open histogram: Isotype control. Grey histogram: Anti-CD137L monoclonal antibody (clone TKS-1).
(B) N9 and OLN93 cells were cultured for 24 h at a 1:1 ratio (1.5×105 each) on plates that had been coated with nothing (PBS) or 10 μg/mL of Fc
control protein or 10 μg/mL of CD137-Fc protein. (C) The rates of OLN93 cell apoptosis in co-cultures with primary microglia from WT or
CD137L-/- mice was determined 48 h after initiation of CD137L signaling by 7-AAD and Annexin V staining. Numbers in quadrants indicate
percentages of cells. These experiments were repeated two to three times with similar results. * P<0.05; ** P<0.01.
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tumor rejection [28]. Yet treatment with the very same
mAb ameliorates collagen-induced arthritis and
chronic graft-versus-host disease [29,30]. But it exacer-
bates acute graft-versus-host disease [31]. The reasons
for these unexpected and difficult to reconcile effects
are not yet understood. Therefore, we are currently
addressing experimentally what influence the absence
of CD137L may have on EAE.
Though our data indicate an important contribution
of the CD137 receptor/ligand system to neuroinflamma-
tory reactions in the CNS of the mouse it is unknown
whether the CD137 receptor/ligand system plays a simi-
lar role in the human brain However, we have shown
previously that CD137 and CD137L are expressed in the
human CNS, and that the expression increases during
inflammation caused by mycobacterial infection [32].
This study extends previous work on CD137L signals
activating myeloid cells by showing for the first time that
CD137L signaling also activates microglia. Further, this
study demonstrates an involvement of the CD137 receptor/
ligand system in neuroinflammatory conditions suggesting
it may also contribute to neurodegenerative diseases.
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